Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-04-12
Based on 635 first isolates · URO · Cystitis (lower UTI) · 2025-04-13 → 2026-04-12
Urology
Per-organism detail: URO urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 87 % (84 %–89 %)
No tissue or blood levels: cystitis only.
Not covered: Pseudomonas aeruginosa (5 %), Proteus mirabilis (5 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
87 %
86 %
n = 42
meropenem MEM
trend · Escherichia coli reserve
82 %
86 %
n = 42
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
78 %
79 %
n = 42
mecillinam MEC
trend · Escherichia coli lower UTI only
73 %
71 %
n = 42
ciprofloxacin CIP
trend · Escherichia coli
72 %
83 %
n = 42
ceftriaxone CRO
trend · Escherichia coli
70 %
69 %
n = 42
65 %
71 %
n = 42
trimethoprim TMP
trend · Escherichia coli lower UTI only
63 %
67 %
n = 42
48 %
45 %
n = 42
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
10 %
n = 42
4 %
10 %
n = 42
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
2 %
n = 42

Most likely organisms for this profile

Escherichia coli
57 %
Enterococcus faecalis
11 %
Klebsiella pneumoniae
10 %
Pseudomonas aeruginosa
5 %
Proteus mirabilis
5 %
Staphylococcus aureus
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.